Peru Registration Transfer: Titular Change Procedure and Strategy

Regulatory information verified as of October 29, 2026

1. Key takeaways

A transfer of a Peruvian sanitary registration (Registro Sanitario, RS) may only be requested by the registration holder (Titular del Registro Sanitario / Peru Registration Holder, PRH) to another qualified pharmaceutical establishment (Establecimiento Farmacéutico), pursuant to Art. 8 of D.S. N° 016-2011-SA (Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios, published on 2011-07-27). The wish of a foreign manufacturer to unilaterally change its holding entity cannot be converted directly into an administrative transfer application. This asymmetry is the defining feature of Peruvian titular changes: the party with the commercial interest in the transfer is not the party with the procedural standing to file it, so the commercial agreement must supply what the administrative procedure does not.

The GRZAN working sequence is contract first, procedure second: settle the commercial transfer of rights and obligations first, then launch the administrative transfer, otherwise a mismatch arises in which the new entity already holds the registration while the former entity still enjoys contractual rights.

2. Legal basis

Regulatory information verified as of October 29, 2026. The correction of Observaciones within 30 working days and the reconsideration period of 15 working days follow the TUPA and constitute Category C data.

3. Expert insights

Insight one: the holder-initiated rule of Art. 8 is a rule of procedural standing. It governs who is entitled to file the transfer application, not who is entitled to decide whether a transfer takes place. Mechanically, the administrative procedure recognizes only the registered holder. The foreign manufacturer, as owner of the product, must use contractual stipulations to oblige the incumbent PRH to file the transfer application. Without such a clause, the manufacturer in Peru ends up in a passive position: the product is its own, the registration stands in someone else’s name, and the registry cannot be changed unilaterally.

Insight two: the requirement of another qualified entity re-binds the transfer to facility licensing. The transferee must itself hold a Droguería (wholesale distributor) or Laboratorio license; a transfer does not create new entity qualification. This means the feasibility of a transfer is determined before the contract is signed: if the transferee’s licenses fall short, there is no transfer application to speak of. When GRZAN facilitates a change of holding entity, the first step is verifying the license category and current status of the transferee; commercial negotiation comes only second.

Insight three: transfer and re-registration are two independent procedures whose windows must be staggered. The validity period of a sanitary registration is 5 years, counted from the date of grant; the window for filing a re-registration opens 1 year before expiry (D.S. N° 016-2011-SA Art. 7; Ley N° 29459 Art. 11). If a transfer overlaps with the re-registration window, the risk arises that the registration expires while the transfer is still under review. GRZAN prefers to schedule transfers in the middle segment of the registration validity period, away from the re-registration window of the final 1 year.

Insight four: a transfer does not exempt the parties from continuity obligations for vigilance and technical documentation. A transfer changes the registered holder, not the substance of the technical documentation or vigilance responsibilities for the product. After the transferee takes over, it must continue to comply with the reporting obligations under R.M. N° 539-2016/MINSA (published on 2016-07-27): serious adverse events within 24 hours, and moderate or mild events within 20 calendar days. If the handover checklist omits the vigilance history, the transferee is directly exposed to a compliance gap from day one.

4. Practical recommendations

1. In the agreement with the incumbent PRH, include a clause obliging it to file the transfer application at the request of the foreign manufacturer, together with remedies for non-performance.
2. Before signing, verify that the transferee holds a Droguería or Laboratorio license and a sanitary operating authorization (Autorización Sanitaria de Funcionamiento) that are currently valid.
3. Schedule the transfer away from the re-registration window of the final 1 year before expiry, preferring the middle segment of the registration validity period.
4. Include technical documentation, vigilance history, retention sample records, and the status of in-transit complaints in the handover checklist.
5. After filing the transfer application, track the procedural status under the TUPA; complete corrections of Observaciones within 30 working days, as failure to correct constitutes grounds for denial.
6. In case of denial, file a reconsideración (Reconsideración) within 15 working days, with an appeal (Apelación) available at the next level.

5. Verification checklist

□ It has been confirmed that the transfer application is filed by the incumbent registration holder (D.S. N° 016-2011-SA Art. 8).

□ The transferee has been verified as a pharmaceutical establishment holding a Droguería or Laboratorio license.

□ The agreement contains the obligation to file the transfer application and remedies for breach.

□ The transfer has been scheduled away from the re-registration window of the final 1 year before expiry.

□ The handover of technical documentation, vigilance history, and retention sample records has been completed.

□ Reminders have been set for the 30 working day correction of Observaciones and the 15 working day reconsideration period.

□ Regulatory information verified as of October 29, 2026.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives. For inquiries, contact info@grzanglobal.com.

*GRZAN Regulatory Affairs Team*